Form 4: Compass Therapeutics Director Receives Stock Options

Compass Therapeutics Director Mary Ann Gray was granted 90,000 stock options with an exercise price of $5.17, vesting upon the earlier of June 10, 2026, or the next annual meeting.

Summary

• Mary Ann Gray, a Director of Compass Therapeutics, Inc. (CMPX), was granted 90,000 stock options.
• The stock options have an exercise price of $5.17 per share.
• The grant vests in full upon the earlier of June 10, 2026, or the date of the next annual meeting of the Company's stockholders.
• The options expire on January 2, 2036.

Sentiment

Score: 7

Explanation: This is a routine compensation disclosure for a director, generally viewed as positive for aligning interests, but it does not represent a significant operational or financial event that would drastically alter the company's outlook.

Positives

• Grant of 90,000 stock options to Director Mary Ann Gray, aligning her interests with shareholder value creation.
• The options have a 10-year expiration date, providing a long-term incentive for the director.

Future Outlook

The vesting schedule for the stock options, tied to either June 10, 2026, or the next annual meeting, indicates a future incentive for the director, aligning her long-term commitment with the company's performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, aiming to incentivize long-term performance and align leadership interests with shareholder returns.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The size of the grant (90,000 options) and the exercise price ($5.17) would typically be evaluated against peer companies of similar market capitalization and stage of development, such as other clinical-stage biotech firms.
• The 10-year term for the options is also a common industry standard, providing a long-term incentive horizon.

Related Party Transactions

• Grant of 90,000 stock options to Mary Ann Gray, a Director of the company, as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential future dilution upon exercise of options, but also benefits from the alignment of the director's interests with long-term company performance and value creation.
• Director (Mary Ann Gray): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance and long-term success.

Next Steps

• The stock options will vest upon the earlier of June 10, 2026, or the date of the next annual meeting of the Company's stockholders.
• The options will expire on January 2, 2036.

Key Dates

Recommendation

This filing reports a routine grant of stock options to an existing director as part of their compensation package. While it serves to align the director's interests with long-term shareholder value, it does not introduce new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing fundamental analysis.

Keywords

Compass Therapeutics, CMPX, Stock Options, Director Compensation, Form 4, Insider Transaction, Equity Grant